FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents

Reuters

05-23

FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents

WESTLAKE VILLAGE, Calif., May 22, 2025 - Arcutis Biotherapeutics Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9456771-en) on May 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537906929"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537906929\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537906929?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 02:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537906929","market":"us","top_or_hot":-1,"title":"FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WESTLAKE VILLAGE, Calif., May 22, 2025 - <a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics Inc.</a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9456771-en) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-23 02:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WESTLAKE VILLAGE, Calif., May 22, 2025 - <a href=\"https://laohu8.com/S/ARQT\">Arcutis Biotherapeutics Inc.</a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9456771-en) on May 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLb8vQGN:1","article_id":"2537906929","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537906929","pubTimestamp":1747937593,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"WESTLAKE VILLAGE, Calif., May 22, 2025 - Arcutis Biotherapeutics Inc. , a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration  has approved the supplemental New Drug Application  for ZORYVE  topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"FDA批准Arcutis Biotherapeutics的ZORYVE®外用泡沫用于成人和青少年斑块型银屑病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":0.9,"NDAQ":0.9},"content_text":"FDA Approves Arcutis Biotherapeutics' ZORYVE® Topical Foam for Plaque Psoriasis Treatment in Adults and Adolescents\n    \n\n        WESTLAKE VILLAGE, Calif., May 22, 2025 - Arcutis Biotherapeutics Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) topical foam 0.3%. This approval allows the use of ZORYVE for treating plaque psoriasis of the scalp and body in both adult and pediatric patients aged 12 and older. The once-daily, steroid-free topical foam is now widely available, offering powerful clearance and rapid itch relief without limitations on duration of use. This marks the fifth FDA approval for ZORYVE in under three years, underscoring its significance in addressing the unmet needs in the plaque psoriasis treatment landscape.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9456771-en) on May 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}